Edwards today presented new data at New York Valves 2026 supporting its transcatheter aortic valve replacement (TAVR) ...

Edwards TAVR data has a strong showing at NY Valves 2026 amid intense industry competition from Abbott Laboratories and Medtronic.

Irvine-based Edwards Lifesciences Corp. today announced newly presented data from several of its clinical trials.

EVOQUE tricuspid valve registry demonstrates more favorable outcomes than pivotal trial SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (EW) today announced data demonstrating successful patient ...

FDA approves new use for Edwards' Sapien 3 heart valve (Reuters) (FDA) ASCO Interviews (CNBC: Incyte, Merck, Roche, Bluebird, Loxo, BMS) House E&C Committee to Vote on User Fee Reauthorization ...

Last month, Edwards Lifesciences recalled its SAPIEN 3 Ultra Delivery System after reports of burst balloons during implantation, resulting in significant difficulty retrieving the valve into the ...

Edwards Lifesciences had a monumental Q4 and full year 2025, growing sales 13.3% to $1.57 billion in the last quarter of the year. The company’s TAVR and TMTT performance are largely being credited ...

“Edwards’ strong fourth quarter and full year performance in 2025 reflect our differentiated strategy with a clear vision around three key elements: focusing solely on structural heart, solving large, ...